The Pharmaceutical Post 20 (30/104)

The Pharmaceutical Post 20The Pharmaceutical Post 20 (30/104)The Pharmaceutical Post 20 - (1/104)The Pharmaceutical Post 20 - (2/104)The Pharmaceutical Post 20 - (3/104)The Pharmaceutical Post 20 - (4/104)The Pharmaceutical Post 20 - (5/104)The Pharmaceutical Post 20 - (6/104)The Pharmaceutical Post 20 - (7/104)The Pharmaceutical Post 20 - (8/104)The Pharmaceutical Post 20 - (9/104)The Pharmaceutical Post 20 - (10/104)The Pharmaceutical Post 20 - (11/104)The Pharmaceutical Post 20 - (12/104)The Pharmaceutical Post 20 - (13/104)The Pharmaceutical Post 20 - (14/104)The Pharmaceutical Post 20 - (15/104)The Pharmaceutical Post 20 - (16/104)The Pharmaceutical Post 20 - (17/104)The Pharmaceutical Post 20 - (18/104)The Pharmaceutical Post 20 - (19/104)The Pharmaceutical Post 20 - (20/104)The Pharmaceutical Post 20 - (21/104)The Pharmaceutical Post 20 - (22/104)The Pharmaceutical Post 20 - (23/104)The Pharmaceutical Post 20 - (24/104)The Pharmaceutical Post 20 - (25/104)The Pharmaceutical Post 20 - (26/104)The Pharmaceutical Post 20 - (27/104)The Pharmaceutical Post 20 - (28/104)The Pharmaceutical Post 20 - (29/104)The Pharmaceutical Post 20 - (30/104)The Pharmaceutical Post 20 - (31/104)The Pharmaceutical Post 20 - (32/104)The Pharmaceutical Post 20 - (33/104)The Pharmaceutical Post 20 - (34/104)The Pharmaceutical Post 20 - (35/104)The Pharmaceutical Post 20 - (36/104)The Pharmaceutical Post 20 - (37/104)The Pharmaceutical Post 20 - (38/104)The Pharmaceutical Post 20 - (39/104)The Pharmaceutical Post 20 - (40/104)The Pharmaceutical Post 20 - (41/104)The Pharmaceutical Post 20 - (42/104)The Pharmaceutical Post 20 - (43/104)The Pharmaceutical Post 20 - (44/104)The Pharmaceutical Post 20 - (45/104)The Pharmaceutical Post 20 - (46/104)The Pharmaceutical Post 20 - (47/104)The Pharmaceutical Post 20 - (48/104)The Pharmaceutical Post 20 - (49/104)The Pharmaceutical Post 20 - (50/104)The Pharmaceutical Post 20 - (51/104)The Pharmaceutical Post 20 - (52/104)The Pharmaceutical Post 20 - (53/104)The Pharmaceutical Post 20 - (54/104)The Pharmaceutical Post 20 - (55/104)The Pharmaceutical Post 20 - (56/104)The Pharmaceutical Post 20 - (57/104)The Pharmaceutical Post 20 - (58/104)The Pharmaceutical Post 20 - (59/104)The Pharmaceutical Post 20 - (60/104)The Pharmaceutical Post 20 - (61/104)The Pharmaceutical Post 20 - (62/104)The Pharmaceutical Post 20 - (63/104)The Pharmaceutical Post 20 - (64/104)The Pharmaceutical Post 20 - (65/104)The Pharmaceutical Post 20 - (66/104)The Pharmaceutical Post 20 - (67/104)The Pharmaceutical Post 20 - (68/104)The Pharmaceutical Post 20 - (69/104)The Pharmaceutical Post 20 - (70/104)The Pharmaceutical Post 20 - (71/104)The Pharmaceutical Post 20 - (72/104)The Pharmaceutical Post 20 - (73/104)The Pharmaceutical Post 20 - (74/104)The Pharmaceutical Post 20 - (75/104)The Pharmaceutical Post 20 - (76/104)The Pharmaceutical Post 20 - (77/104)The Pharmaceutical Post 20 - (78/104)The Pharmaceutical Post 20 - (79/104)The Pharmaceutical Post 20 - (80/104)The Pharmaceutical Post 20 - (81/104)The Pharmaceutical Post 20 - (82/104)The Pharmaceutical Post 20 - (83/104)The Pharmaceutical Post 20 - (84/104)The Pharmaceutical Post 20 - (85/104)The Pharmaceutical Post 20 - (86/104)The Pharmaceutical Post 20 - (87/104)The Pharmaceutical Post 20 - (88/104)The Pharmaceutical Post 20 - (89/104)The Pharmaceutical Post 20 - (90/104)The Pharmaceutical Post 20 - (91/104)The Pharmaceutical Post 20 - (92/104)The Pharmaceutical Post 20 - (93/104)The Pharmaceutical Post 20 - (94/104)The Pharmaceutical Post 20 - (95/104)The Pharmaceutical Post 20 - (96/104)The Pharmaceutical Post 20 - (97/104)The Pharmaceutical Post 20 - (98/104)The Pharmaceutical Post 20 - (99/104)The Pharmaceutical Post 20 - (100/104)The Pharmaceutical Post 20 - (101/104)The Pharmaceutical Post 20 - (102/104)The Pharmaceutical Post 20 - (103/104)The Pharmaceutical Post 20 - (104/104) OLON Le chemin d'Olon vers la durabilité : Transformer les défis en opportunités La pandémie de COVID-19 a indéniablement marqué le début d’une nouvelle ère de « polycrise », caractérisée par des crises continues, fréquentes et dévastatrices. En tant que principal fournisseur d'API, avec son siège social en Italie et un réseau de fabrication mon- dial comprenant 11 sites de production et 7 centres de recherche. Dans le monde entier, Olon a fait face à ce moment difficile en essayant de transformer les crises en opportunités et rendre son modèle opérationnel complexe résilient et flexible. Le facteur de réussite est la durabilité. Olon's Path to Sustainability: Transforming Challenges into Opportunities The COVID-19 pandemic undeniably marked the start of a new era of “polycrisis,” charac- terisedby continuous, frequent and devastating crises. As leading API supplier, with HQs in Italy and a global manufacturing network comprising 11 production sites and 7 research cen- ters worldwide, Olon has been facing this challenging moment trying to transform crises into opportunities and making its complex operational model resilient and flexible. One of the key factors to be successful is sustainability. 30The Pharmaceutical Post 20 / Octobre - 2024